SLC5A2 and cancer: In another study by Hwang et al., conducted in an Asian population, the analysis of cancer patients demonstrated a 20% reduction in cardiovascular events, including heart failure hospitalization, acute myocardial infarction, ischemic stroke, and all-cause mortality in patients receiving SGLT2 inhibitors compared to both non-diabetic individuals and diabetic patients not treated with SGLT2i [67].